PYX-201 monotherapy study in 2L and 3L HNSCC patients who are platinum and PD-1 inhibitor experienced
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs PYX-201 (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 25 Nov 2024 New trial record
- 20 Nov 2024 According to Pyxis Oncology media release, preliminary clinical data readout expected in the second half of 2025.